The Impact and Control of Emerging and Re-Emerging Viral Diseases in the Environment: An African Perspective

Shenge, Juliet Adamma; Opayele, Adewale Victor

doi:10.1007/978-3-030-35296-7_7

Cited by 5 publications

(2 citation statements)

References 100 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Monkeypox, a zoonotic viral disease caused by the monkeypox virus (MPXV), has resulted >85,000 confirmed MPXV cases and >89 deaths worldwide since January 2022 [ 2 ]; it was declared a public health emergency by the WHO in July 2022 [ 3 ]. Furthermore, more recently, the Marburg virus [ 4 , 5 ] has emerged.…”

Section: Introductionmentioning

confidence: 99%

“…The interaction between animals, humans and the environment is now considered under the One Health approach to mitigating infectious disease. One Health is an important concept, as approximately 80% of human viral pathogens are zoonotic with climatic, agricultural and anthropological factors contributing to disease outbreak [ 4 ]. Furthermore, zoonotic viruses regularly result in spillover events in livestock animals which act as reservoirs for human exposure [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bioprocessing and the Production of Antiviral Biologics in the Prevention and Treatment of Viral Infectious Disease

Meade

Rowan²,

Garvey

2023

Vaccines

View full text Add to dashboard Cite

Emerging, re-emerging and zoonotic viral pathogens represent a serious threat to human health, resulting in morbidity, mortality and potentially economic instability at a global scale. Certainly, the recent emergence of the novel SARS-CoV-2 virus (and its variants) highlighted the impact of such pathogens, with the pandemic creating unprecedented and continued demands for the accelerated production of antiviral therapeutics. With limited effective small molecule therapies available for metaphylaxis, vaccination programs have been the mainstay against virulent viral species. Traditional vaccines remain highly effective at providing high antibody titres, but are, however, slow to manufacture in times of emergency. The limitations of traditional vaccine modalities may be overcome by novel strategies, as outlined herein. To prevent future disease outbreaks, paradigm shift changes in manufacturing and distribution are necessary to advance the production of vaccines, monoclonal antibodies, cytokines and other antiviral therapies. Accelerated paths for antivirals have been made possible due to advances in bioprocessing, leading to the production of novel antiviral agents. This review outlines the role of bioprocessing in the production of biologics and advances in mitigating viral infectious disease. In an era of emerging viral diseases and the proliferation of antimicrobial resistance, this review provides insight into a significant method of antiviral agent production which is key to protecting public health.

show abstract